Sanofi Announces Launch of AVAXIM Junior in the UK for Active Immunisation Against Infection Caused by the Hepatitis A Virus in Children Aged 12 Months to 15 Years
Sanofi (EURONEXT: SAN and NASDAQ: SNY) has today announced the launch of AVAXIM Junior in the UK, an inactive hepatitis A vaccine indicated for use in children aged 12 months to 15 years inclusive to
Source: finanznachrichten.de